🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
20,548
Companies
1,769
Drugs tracked
4,797

Quick answer

NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

1,557 results for “placebo” Clear

  1. Placebo to Remibrutinib (LOU064) XX mg film-coated tablet, LOU064, LOU064, Placebo to Remibrutinib (LOU064) XX mg film-coated tablet

    Novartis Pharmaceuticals

    Hidradenitis Suppurativa (HS)

    phase 3 small molecule active

    1 trial

  2. Placebo to Remibrutinib (LOU064) film-coated tablets, LOU064

    Novartis Pharmaceuticals

    Secondary progressive multiple sclerosis

    phase 3 small molecule active

    1 trial

  3. Placebo to TQJ230 80 mg/0.8 mL Solution for injection in pre-filled syringe with needle safety device, TQJ230

    Novartis Pharmaceuticals

    Cardiovascular Disease

    phase 3 small molecule active

    1 trial

  4. Placebo to Test and Comparator, DoriDuo, Mebocaína Anti-Inflam, 1.2 mg + 3 mg, comprimidos para chupar

    Medice Arzneimittel Pütter GmbH & Co. KG

    acute pharyngitis

    phase 3 small molecule active

    1 trial

  5. Placebo to Upadacitinib

    AbbVie

    Rheumatoid Arthritis

    phase 3 small molecule completed

    1 trial

  6. Placebo to VAY736 150 mg/1 mL Solution for injection in pre-filled syringe, VAY736, -

    Novartis Pharmaceuticals

    Sjögren’s Syndrome

    phase 3 small molecule active

    1 trial

  7. Placebo to capivasertib, Capivasertib, Bendadocel 20 mg/ml Konzentrat zur Herstellung einer Infusionslösung, Docetaxel Accord 80 mg/4 ml concentrate for solution for infusion, Capivasertib, Docetaxel Hikma 80 mg/4 ml Konzentrat zur Herstellung einer Infusionslösung

    AstraZeneca AB

    Metastatic Castration Resistant Prostate Cancer (mCRPC)

    phase 3 small molecule active

    1 trial

  8. Placebo to doravirine/ islatravir, MK-8591A, Placebo to bictegravir/ emtricitabine/ tenofovir alafenamide, Biktarvy 50 mg/200 mg/25 mg film-coated tablets, Biktarvy 50 mg/200 mg/25 mg film-coated tablets

    Merck Sharp and Dohme

    HIV-1 Infection

    phase 3 small molecule active

    1 trial

  9. Placebo to match 10 mg, Placebo to match 5 mg

    Gilead Sciences Pty Limited

    Primary Biliary Cholangitis

    phase 3 small molecule active

    1 trial

  10. Placebo to match 100mg tablet, Lasmiditan, LASMIDITAN, Placebo to match 50mg tablet, LASMIDITAN, Placebo to match 100mg film coated tablet, Lasmiditan, Placebo to match 25mg tablet, Lasmitidan, Placebo to match 50mg film coated tablet

    Eli Lilly Co.

    Migraine

    phase 3 small molecule active

    1 trial

  11. Placebo to match Apremilast film-coated tablets, deucravacitinib, Placebo to match deucravacitinib tablet, Otezla 10mg, 20mg, 30 mg film-coated tablets

    Bristol-Myers Squibb Australia Pty Ltd

    Active Psoriatic Arthritis

    phase 3 small molecule active

    1 trial

  12. Placebo to match Choline Chloride for Injection, Choline Chloride for Injection

    Protara Therapeutics

    Intestinal Failure

    phase 3 small molecule active

    1 trial

  13. Placebo to match LY

    Eli Lilly Co.

    Overweight or Obesity, OSA (Obstructive Sleep Apnea)

    phase 3 small molecule active

    1 trial

  14. Placebo to match LY, Brenipatide, Brenipatide, Brenipatide

    Eli Lilly Co.

    Alcohol Use Disorder

    phase 3 small molecule active

    1 trial

  15. Placebo to match LY, Muvalaplin

    Eli Lilly Co.

    Elevated Lp(a), Atherosclerotic Cardiovascular Disease (ASCVD)

    phase 3 small molecule active

    1 trial

  16. Placebo to match LY, PEMBROLIZUMAB , DURVALUMAB

    Eli Lilly Co.

    Resected or Unresectable KRAS G12C-mutant Non-Small Cell Lung Cancer

    phase 3 small molecule active

    1 trial

  17. Placebo to match LY, Retatrutide, Retatrutide, Retatrutide, Retatrutide, Retatrutide

    Eli Lilly Co.

    Overweight, Chronic Low Back Pain (CLBP), Obesity

    phase 3 small molecule active

    1 trial

  18. Placebo to match LY3527723, Placebo to match LY3527723, SELPERCATINIB, SELPERCATINIB

    Eli Lilly Co.

    RET fusion-Positive NSCLC

    phase 3 small molecule active

    1 trial

  19. Placebo to match LY3537982, PEMBROLIZUMAB , PEMETREXED , CARBOPLATIN , CISPLATIN

    Eli Lilly Co.

    Stage IIIB-IIIC or Stage IV KRAS G12C-mutant non-small cell lung cancer

    phase 3 small molecule active

    1 trial

  20. Placebo to match Linaprazan glurate 50mg, Placebo to match Lansoprazole 30 mg, Linaprazan glurate, LANSOPRAZOLE

    Lacuna Pharma Pty Ltd

    Erosive esophagitis (EE) due to gastroesophageal reflux disease (GERD)

    phase 3 small molecule active

    1 trial

  21. Placebo to match Paltusotine tablets 20 mg, Paltusotine tablets

    Lacuna Pharma Pty Ltd

    Acromegaly

    phase 3 small molecule active

    1 trial

  22. Placebo to match abemaciclib, Verzenios 50 mg film-coated tablets, FULVESTRANT

    Eli Lilly Co.

    Breast Neoplasm, Neoplasm Metastasis

    phase 3 small molecule active

    1 trial

  23. Placebo to match ly, Eloralintide, Eloralintide, Eloralintide, Eloralintide

    Eli Lilly Co.

    Obesity, Overweight

    phase 3 small molecule active

    1 trial

  24. Placebo to match ly, Orforglipron, Orforglipron, Orforglipron, Orforglipron, Orforglipron, Orforglipron

    Eli Lilly Co.

    Urinary Incontinence, Stress

    phase 3 small molecule active

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources